| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Radiopharm Theranostics Limited American Depositary Shares$4.29
+0.01 (+0.23%)
Market Cap
55.05 M
EPS
-2.94
P/E Ratio
-1.58 $
Value Trade
145.74 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
35.10 K
52 Week Range
3.62 - 16.25
% held by Insiders
-
% held by Institutions
4.06 %
Enterprise Value
30.80 M
Total Shares
-
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Radiopharm Theranostics Limited American Depositary Shares
188Total events
14Upcoming
45Tier-1 (high impact)
2024 – 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutClinical Data
Subscribe to view catalyst details
TBD
◆Topline ReadoutClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RAD101 Fast Track | brain metastases | Phase 2b | 2026-07-22 | concordance: 93%; sensitivity: 86% (12/14) | Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases Read More | |
RAD101 Fast Track | brain metastases | Phase 2b | 2026-07-22 | concordance: 93%; sensitivity: 86% (12/14) | Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases Read More | |
RAD101 Fast Track | brain metastases | Phase 2b | 2026-07-22 | concordance: 93%; sensitivity: 86% (12/14) | Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RADX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RADX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-RADX
Jul 22, 2026▲ +0.2%today
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
Radiopharm Theranostics announced positive results from the Phase 1 trial of RAD204, a PD-L1-targeted radiotherapeutic for advanced solid tumors. The first patient achieved a durable RECIST-confirmed Partial Response, remaining progression-free for over seven months. The second patient also shows early signs of tumor shrinkage. RAD204 has been well-tolerated with no significant toxicities reported.
Read more →-RADX
Jul 22, 2026▲ +0.2%today
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics announced positive results from its Phase 2b trial of RAD101, achieving a 93% concordance with MRI for diagnosing brain metastases. The trial demonstrated an 86% sensitivity in 14 patients, supporting the advancement to a Phase 3 trial planned for Q4 2026. The company aims to address a significant market need for effective imaging in neuro-oncology.
Read more →-RADX
Jun 5, 2026▼ -6.7%on this news
RAD Presentation June 2026
Radiopharm Theranostics has made significant progress with the dosing of its first patient in the Phase 1/2a clinical study of BetaBart (RV-01). Additionally, the company has received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. The company has also provided positive updates across its four clinical programs.
Read more →-RADX
Jun 3, 2026Appendix 3H - Notification of cessation of securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday
Radiopharm Theranostics Limited announced the cessation of certain securities, specifically 505,598 options expiring on various dates. This cessation is attributed to the expiry of options or other convertible securities that were not exercised or converted. The announcement details the company’s issued capital following this cessation, with substantial asset holdings in other options and ordinary shares. The entity did not provide any consideration for the cessation of the securities.
Read more →-RADX
May 14, 2026Zacks Small-Cap Research 2026
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study for BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, positive updates were shared regarding four of its clinical programs.
Read more →-RADX
May 1, 2026ASX ANNOUNCEMENT 1 May 2026 Financial Services and Company Secretary Changes Sydney, Australia - 1 May 2026 - Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company
Radiopharm Theranostics announced changes in its financial services and company secretary roles. Mr. Phillip Hains has resigned as Chief Financial Officer and Joint Company Secretary, with the Board expressing gratitude for his contributions. Mr. Aaron Laurita has been appointed to assume the CFO role, while Ms. Amritha Sushil will serve as Joint Company Secretary, enhancing the company's governance structure. These changes reflect Radiopharm's commitment to maintaining effective leadership in their operations.
Read more →-RADX
Apr 23, 2026ASX ANNOUNCEMENT 23 April 2026 Radiopharm Theranostics Reports Business Update Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announc
Radiopharm Theranostics has completed enrollment in a Phase 2b trial for RAD 101, achieving a promising 90% concordance with MRI in patients with recurrent brain metastases. The company also presented encouraging data for RAD 202, which indicated good tumor uptake and a favorable safety profile. Furthermore, the Data and Safety Monitoring Committee has recommended advancing RAD 202 to higher dosing levels, highlighting its potential for effective cancer treatment. Radiopharm is enhancing its pipeline with two new First-In-Human clinical trials for additional radiotherapeutics.
Read more →-RADX
Apr 20, 2026Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
Radiopharm Theranostics presented initial findings from its Phase 1 HEAT clinical trial for 177Lu-RAD202 at the AACR Annual Meeting 2026. The trial demonstrated promising tumor uptake and a favorable safety profile in patients with HER2-positive solid tumors. The Data Safety and Monitoring Committee has approved advancing to a higher dose, indicating potential for further therapeutic evaluation.
Read more →-RADX
Apr 20, 2026ASX ANNOUNCEMENT
Radiopharm Theranostics has announced initial findings from their Phase 1 HEAT clinical trial for 177Lu-RAD202, a novel HER2-targeted radiopharmaceutical. Presented at the AACR Annual Meeting 2026, initial results indicate promising tumor uptake and a favorable safety profile at the lowest dose level. Following these results, the Data Safety and Monitoring Committee has approved advancing the trial to the next dose level of 130 mCi, indicating potential for further therapeutic effectiveness. This study is significant as it involves a heavily pre-treated patient population with unmet medical needs in advanced HER2-positive cancers.
Read more →-RADX
Apr 16, 2026ASX ANNOUNCEMENT 16 APRIL 2026 Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases Interim data to date showed 90% concordance with MRI (the primary en
Radiopharm Theranostics has completed the enrollment of the final patient in its U.S. Phase 2b imaging trial for RAD 101, which targets brain metastases. Interim results indicate a 90% concordance with MRI, which positions the product favorably in detecting recurrent brain metastases. The CEO expressed optimism about the upcoming clinical trial readout scheduled for June 2026 and plans to initiate the next Phase 3 trial. The company received FDA Fast Track Designation for RAD 101, which highlights its significance in addressing a crucial unmet medical need in oncology.
Read more →-RADX
Apr 7, 2026ASX ANNOUNCEMENT 7 April 2026 Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selec
Radiopharm Theranostics has entered into a Clinical Supply Agreement with Siemens Healthineers for RAD101, a novel imaging agent for diagnosing recurrent brain metastases. Interim analysis from the Phase 2b trial revealed significant tumor uptake and a 90% concordance rate with MRI. The partnership is crucial for scaling up production for a forthcoming Phase 3 trial. Additionally, RAD101 has received FDA Fast Track Designation, indicating its potential importance in U.S. clinical settings.
Read more →-RADX
Mar 27, 2026ASX ANNOUNCEMENT 27 March 2026 Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and
Radiopharm Theranostics announced the dosing of the first patient in its Phase 1 clinical trial of RAD 402, aimed at treating advanced prostate cancer. The trial will assess the drug's safety, tolerability, and preliminary clinical activity. RAD 402 is a monoclonal antibody targeting KLK3, with promising preclinical results indicating effective tumor targeting and minimal off-target exposure. The company plans to share data from the first two dose levels in the second half of 2026.
Read more →-RADX
Mar 24, 2026▼ -10.8%on this newsshared move
ASX ANNOUNCEMENT 24 March 2026 Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases 90% of patients dosed with RAD 101 and
Radiopharm Theranostics announced positive results from the second interim analysis of its Phase 2b clinical trial of RAD 101 in patients with brain metastases. The trial showed that 90% of the 20 evaluated patients achieved concordance with MRI imaging, meeting the primary endpoint. Additionally, the early data from five patients indicated an encouraging trend in sensitivity and specificity for the imaging agent. The company looks forward to final results from the full study, which will guide future trials.
Read more →-RADX
Mar 19, 2026ASX ANNOUNCEMENT 19 March 2026 Radiopharm to present at NWR Virtual Healthcare Conference Sydney, Australia- 19 March 2026 - Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmace
Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced its upcoming presentation at the NWR Virtual Healthcare Conference scheduled for March 25, 2026. The CEO, Riccardo Canevari, will discuss the company’s innovative approaches in oncology radiopharmaceuticals. This event aims to connect Radiopharm with shareholders, investors, and other interested parties. A recording of the presentation will be accessible to the public after the live session.
Read more →-RADX
Mar 10, 2026RAD Presentation March 2026
Radiopharm Theranostics has made significant progress with its BetaBart (RV-01) program, having dosed the first patient in a Phase 1/2a clinical study. The company also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, positive updates were shared across four of their clinical programs, indicating a strong outlook for the company.
Read more →-RADX
Feb 27, 2026RAD THERANOSTICS RADIOPHARM Interim Report: Half Year Ended 31December 2025
Radiopharm Theranostics Limited reported its interim financial results for the half year ended December 31, 2025, revealing a significant loss of $28.2 million, primarily due to increased research and development investments. Despite the losses, the company is making strides in its clinical programs, particularly with RAD 101 achieving a 92% concordance in a key Phase 2b trial for brain metastases. Additionally, positive safety data for RAD 202 and RAD 204 underscore promising developments in treating HER 2 positive cancers and PD-L1 driven malignancies. The company expects further advancements in its clinical pipeline, with multiple trials set to initiate in early 2026.
Read more →-RADX
Feb 25, 2026Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
Radiopharm Theranostics has successfully dosed its first patient in the Phase 1/2a clinical study of BetaBart (RV-01). This milestone follows the recent IND approval from the US FDA, allowing the company to explore the therapeutic potential of targeting B7H3. The study aims to assess the safety and efficacy of this innovative treatment.
Read more →-RADX
Feb 24, 2026ASX ANNOUNCEMENT 24 February 2026 Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radi
Radiopharm Theranostics has successfully dosed the first patient in a Phase 1/2a clinical trial for its radiotherapeutic agent 177Lu-BetaBart (RV-01). This pivotal trial aims to evaluate the safety, biodistribution, and preliminary anti-tumor activity of the agent, which has previously shown significant efficacy in preclinical animal studies. The trial specifically targets patients with advanced solid tumors, and the drug aims to leverage the targeting capabilities of B7-H3, an immune checkpoint molecule associated with several tumor types.
Read more →-RADX
Jan 30, 2026Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
Radiopharm Theranostics has made significant strides in its clinical programs, including the dosing of the first patient in a Phase 1/2a study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments highlight the company's commitment to advancing its innovative therapies.
Read more →-RADX
Jan 28, 2026Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Radiopharm Theranostics reported positive interim results from its Phase 2b trial of RAD 101, showing 92% MRI concordance in patients with brain metastases. The company has a solid cash position of approximately $34.52 million, allowing it to advance its clinical pipeline into 2027. Additional data from Phase 1 trials for RAD 202 and RAD 204 are expected in mid-2026.
Read more →-RADX
Jan 28, 2026ASX ANNOUNCEMENT 28 January 2026 Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the prima
Radiopharm Theranostics announced its half-year financial results for fiscal 2026, highlighting significant progress in their clinical pipeline. The interim results from a Phase 2b clinical trial of RAD 101 showed that 92% of evaluable patients met the primary endpoint for MRI imaging concordance. The company also reported a solid cash position of approximately $34.52 million, ensuring operational continuity into 2027. Several clinical milestones are set for 2026, including ongoing trials for various promising radiotherapeutics.
Read more →-RADX
Jan 12, 2026ASX ANNOUNCEMENT 12 JANUARY 2026 RAD Increases Ownership in Radiopharm Ventures to 87.5% Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics Leading
Radiopharm Theranostics has increased its ownership stake in Radiopharm Ventures to 87.5%, reflecting confidence in the joint venture's progress in cancer therapeutics. This decision accompanies the advancement of their B7H3 candidate and other preclinical assets. The company is expecting first-in-human trial results for their monoclonal antibody Betabart (RV01) in early 2026 after receiving FDA clearance. The joint venture aims to develop novel radiopharmaceutical products for cancer treatment leveraging MD Anderson's expertise.
Read more →-RADX
Dec 19, 2025▼ -5.5%on this news
Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documen
Radiopharm Theranostics Limited (ASX: RAD) filed a Change of Director's Interest Notice concerning Ian Turner, indicating an increase in his holdings of unlisted options from 18,167,928 to 24,981,928. The adjustments were approved by shareholders during an Annual General Meeting held on November 20, 2025. The notice reflects the requirements under listing rule 3.19A.2, emphasizing transparency regarding directors' interests in the company. The notice confirms that no transactions occurred during a closed period requiring prior written clearance.
Read more →-RADX
Dec 15, 2025▲ +149.5%on this news
ASX ANNOUNCEMENT 15 December 2025 Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases 92% of evaluable patients at interim analys
Radiopharm Theranostics announced that 92% of patients in the RAD 101 Phase 2b clinical trial for brain metastases achieved concordance with MRI imaging at an interim analysis. This small-molecule imaging agent, targeting fatty acid synthase, may significantly impact patient management for over 300,000 U.S. patients diagnosed annually with cerebral metastases. The promising results strengthen plans for a pivotal study expected to commence by the end of 2026. Additionally, RAD 101 has received FDA Fast Track Designation, which underscores its potential market value.
Read more →-RADX
Dec 4, 2025ASX ANNOUNCEMENT 3 December 2025 Results of General Meeting Sydney, Australia - Wednesday, 3 December 2025 - Radiopharm Theranostics Limited (ASX: RAD; Nasdaq: RADX) advises that all resolutions considered at the General
Radiopharm Theranostics Limited announced that all resolutions presented at its General Meeting held on December 3, 2025, were approved by poll. The company provided detailed voting results in accordance with ASX Listing Rules, showing significant support for each resolution, including the approval of placement shares and options. This successful outcome reflects the favorable reception of the company's strategies among its shareholders.
Read more →-RADX
Nov 25, 2025Appendix 3Z Final Director's Interest Notice Rule 3.19A.3 Appendix 3Z Final Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given
Radiopharm Theranostics Limited (ASX: RAD) submitted a Final Director's Interest Notice regarding director Leila Alland. The notice indicated the date she ceased to be a director on November 20, 2025, and specified that any additional information or documents not currently available must be provided to the ASX when they become available. The notice is in compliance with ASX listing rule 3.19A.3 and outlines the obligations under the Corporations Act. No specific interests or contracts were disclosed in the notice.
Read more →-RADX
Nov 20, 2025NOVEMBER 20 , 202 5 NASDAQ: RADX / ASX: RAD Annual General Meeting Notice & Disclaimer 2 The information in this presentation does not constitute personal investment advice . The presentation is not intended to be compre
Radiopharm Theranostics Ltd. is preparing for its upcoming Annual General Meeting, as detailed in a recent presentation. The company, which is advancing several innovative radiopharmaceuticals, is currently involved in multiple clinical trials targeting various cancers. Risks highlighted in the presentation include potential delays in trial completion and the need for additional data from regulatory authorities. Additionally, the financial outlook points to a cash runway extending into 2027, ensuring ongoing operation amid clinical developments.
Read more →-RADX
Nov 19, 2025▲ +7.4%on this newsshared move
Appendix 3X Initial Director's Interest Notice Rule 3.19A.1 Appendix 3X Initial Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents g
Radiopharm Theranostics Limited (ASX: RAD) has issued an Initial Director's Interest Notice for Bruce Goodwin, who was appointed as a director on November 19, 2025. The notice includes the requirement to disclose any relevant interests in securities and contracts as mandated by ASX listing rules. Currently, specific details regarding Goodwin's interests were not provided, indicating that more information will be submitted to ASX as it becomes available.
Read more →-RADX
Nov 18, 2025ASX ANNOUNCEMENT 18 NOVEMBER 2025 Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer RAD 402 is a humanized IgG1 internalized by p
Radiopharm Theranostics has received approval from the Bellberry Human Research Ethics Committee to initiate a Phase 1 clinical trial of RAD 402 for advanced prostate cancer. RAD 402 is a KLK3-targeting monoclonal antibody radiolabeled with the radionuclide 161Tb, aimed at providing safer, more effective treatment options. The company is optimistic about the potential of RAD 402, supported by encouraging preclinical biodistribution studies and regulatory endorsement. This marks a significant step forward for both the company and patients facing metastatic prostate cancer.
Read more →-RADX
Nov 17, 2025ASX ANNOUNCEMENT 17 November 2025 Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases Early patient data from Phase 2b clinical trial showed significant and s
Radiopharm Theranostics announced a milestone in its Phase 2b clinical trial for RAD101, reaching 50% patient enrollment. Early data indicate significant and selective tumor uptake in brain metastases when compared to conventional MRI. This promising development is pivotal for differentiating between tumor recurrence and radiation effects in patients. The full enrollment is anticipated to be completed by mid-2026, with topline results expected afterwards.
Read more →-RADX
Nov 12, 2025ASX ANNOUNCEMENT 12 November 2025 Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 Data Safety Monitoring Committee approves advancing to a higher do
Radiopharm Theranostics has announced the start of enrollment for the third cohort in its Phase 1 dose escalation clinical trial of 177Lu-RAD204, targeting patients with PD-L1 positive advanced cancers. The trial has received approval from the Data Safety Monitoring Committee to escalate the dose to 90mCi for this cohort. Initial results from earlier cohorts have shown favorable tumor uptake and a good safety profile. This advancement is considered a significant milestone for the company as it seeks to improve treatment outcomes for patients facing serious cancers.
Read more →-RADX
Nov 4, 2025Notice of Extraordinary General Meeting Radiopharm Theranostics Limited ACN 647 877 889 Notice of Extraordinary General Meeting Radiopharm Theranostics Limited ACN 647 877 889 Notice is given that the Extraordinary Gener
Radiopharm Theranostics Limited has announced an Extraordinary General Meeting scheduled for December 3, 2025. The meeting will take place at a physical venue in Carlton, Victoria, as well as virtually via the Automic Investor Portal. Shareholders will have opportunities to vote and ask questions regarding several resolutions, including the ratification of previously issued shares and proposals for second tranche placements and options. Directors recommend shareholder approval for all items on the agenda.
Read more →-RADX
Nov 3, 2025Zacks Small-Cap Research
Radiopharm Theranostics has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with Betabart (RV-01). The company has also dosed its first patient in a Phase 1/2a clinical study. Additionally, positive clinical updates were provided across four programs, showcasing the company's progress.
Read more →-RADX
Oct 28, 2025ASX ANNOUNCEMENT 28 OCTOBER 2025 QUARTERLY ACTIVITIES AND CASH FLOW REPORT QUARTER ENDED 30 SEPTEMBER 2025 Sydney, Australia - 28 October 2025 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a develop
Radiopharm Theranostics (ASX:RAD) announced its quarterly activities and cash flow report for the period ending September 30, 2025. The company reported positive developments in multiple radiopharmaceutical programs, including RAD 101's promising Phase 2b study for brain metastases and RAD 202’s Phase 1 HEAT trial with favorable safety profiles. Additionally, the firm obtained FDA approval to initiate a Phase I trial for the novel therapy Betabart (RV-01). To strengthen its financial position, Radiopharm completed a A$35 million institutional placement and launched a A$5 million share purchase plan.
Read more →-RADX
Oct 23, 2025Notice of Annual General Meeting Radiopharm Theranostics Limited ACN 647 877 889 Notice of Annual General Meeting Radiopharm Theranostics Limited ACN 647 877 889 Notice is given that the Annual General Meeting of Radioph
Radiopharm Theranostics Limited will hold its Annual General Meeting (AGM) on November 20, 2025, at Level 3, 62 Lygon Street, Carlton, and virtually via the Automic Investor Portal. Shareholders are encouraged to register in advance for virtual attendance, which includes the ability to vote and ask questions. Key items on the agenda include financial reports and several resolutions requiring shareholder votes, including the re-election of directors and approval of incentive options.
Read more →-RADX
Oct 20, 2025▲ +6.3%on this newsshared move
Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs
Radiopharm Theranostics has announced positive clinical updates, including the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and receiving IND approval from the US FDA to target B7H3. These developments mark significant progress in their clinical programs, reflecting the company's commitment to advancing innovative therapies.
Read more →-RADX
Oct 20, 2025▲ +6.3%on this newsshared move
CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025
Radiopharm Theranostics has announced the receipt of IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with BetaBart (RV-01). Additionally, the company has provided positive updates across four of its clinical programs. This marks a significant step forward in their clinical development efforts.
Read more →-RADX
Oct 7, 2025Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Date of this announcement Tuesday
Radiopharm Theranostics Limited has announced the issuance of 107,520,000 unquoted equity securities under an employee incentive scheme, with a restriction on transfer until a specified date. These securities will rank equally with existing issued securities in the same class. This announcement highlights the company's efforts to incentivize employee participation, though the specifics of any potential risks or downsides were not detailed.
Read more →-RADX
Oct 1, 2025ASX ANNOUNCEMENT October 1 st , 2025 Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 HEAT' Dose Escalation Clinical Trial Phase
Radiopharm Theranostics announced a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to accelerate its Phase 1 HEAT' clinical trial of 177Lu-RAD202 for patients with HER2-positive advanced solid tumors. The DSMC confirmed positive safety and distribution data for the initial dose, allowing progression to a higher dose level of 75mCi. The company is on track to enroll the second cohort by Q4 2025 and expects to share data from the first two cohorts by the end of the year.
Read more →-RADX
Sep 30, 2025Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan RAD has received firm commitments for a A$35 million capital raising via an institutional private placement to new A
Radiopharm Theranostics Limited has successfully completed a A$35 million capital raising through a private placement with institutional investors, including Lantheus Holdings, Inc. The funds raised will be utilized to advance the company's six clinical programs. Additionally, Radiopharm is launching a Share Purchase Plan (SPP) to raise up to A$5 million for existing shareholders. The completion of these financial initiatives is anticipated to strengthen the company's market positioning and operational capabilities.
Read more →-RADX
Sep 30, 2025ASX ANNOUNCEMENT Radiopharm Theranostics Partners with Starpharma on Research and Option Agreement to Develop a Novel Radiotherapy Asset Program to incorporate Radiopharm's Theranostics' radiopharmaceutical molecule with
Radiopharm Theranostics has signed a research and option agreement with Starpharma to develop a radiopharmaceutical molecule using Starpharma's DEP platform technology. This partnership is aimed at creating a new drug conjugate for targeted cancer treatment. The collaboration is seen as a significant advancement in Radiopharm's initiative to address high unmet medical needs in oncology. Starpharma's DEP platform technology is expected to enhance the effectiveness of the developed therapies, marking progress for both companies in the field of biopharmaceuticals.
Read more →-RADX
Sep 17, 2025Radiopharm Theranostics Limited Corporate Governance Statement 30 June 2025 This Corporate Governance Statement of Radiopharm Theranostics Limited (the "Company") is prepared in accordance with ASX Listing Rule 4.10.3. I
Radiopharm Theranostics Limited has published its Corporate Governance Statement for the financial year ending 30 June 2025, demonstrating compliance with ASX Listing Rule 4.10.3. The statement outlines the Company's commitment to ethical practices, integrity in reporting, and a structured governance framework adhering to ASX Principles and Recommendations. It details the Board's responsibilities, diversity policies, and processes for performance reviews and appointments. The Company aims to uphold high governance standards while valuing diversity and equal opportunity among its workforce.
Read more →-RADX
Sep 15, 2025ASX ANNOUNCEMENT 15 SEPTEMBER 2025 RADIOPHARM TO HOST PIVALATE (BRAIN METS) KEY OPINION LEADER WEBINAR Sydney, Australia - 15 September 2025 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer
Radiopharm Theranostics is set to host a webinar on 25 September 2025 focused on the novel radiotracer Pivalate, used for detecting relapsed brain metastases from solid tumors. Key opinion leaders, including Dr. Ramji Rajendran, will discuss the challenges in accurately detecting brain metastases and the clinical potential of Pivalate. This innovation aims to overcome current limitations of imaging techniques like FDG PET and MRI, offering a more precise tool for clinicians. The company continues to highlight its commitment to developing advanced cancer diagnostics and therapeutics.
Read more →-RADX
Aug 29, 2025Radiopharm Theranostics Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Radiopharm Theranostics Limited ABN: 57 647 877 889 Reporting period: For the year ended 30 June 2025 Previous perio
Radiopharm Theranostics Limited has released its preliminary financial report for the year ending June 30, 2025. The company experienced a remarkable 1114.3% increase in revenue from contracts with customers, totaling $3,633,422, while their net assets improved significantly to $42,871,904. However, the firm reported a loss after tax of $38,342,457, although this marked a reduction compared to the previous loss of $47,949,119. The financial statements remain in the audit process, with completed audited statements expected by mid-September 2025.
Read more →-RADX
Aug 21, 2025▼ -15.3%on this news
ASX ANNOUNCEMENT 21 AUGUST 2025 RADIOPHARM TO HOST KEY OPINION LEADER WEBINAR SERIES Sydney, Australia - 21 August 2025 - Radiopharm Theranostics (ASX: RAD, "Radiopharm" or the "Company"), a developer of a world-class pl
Radiopharm Theranostics (ASX: RAD) has announced a series of webinars featuring key opinion leaders focused on radiopharmaceutical therapies for oncology, particularly prostate cancer treatment. The first session is scheduled for August 27, 2025, and will include discussions on novel therapeutic strategies targeting B7H3. Dr. Oliver Sartor, an esteemed oncologist, along with other prominent experts, will share insights and advancements in this field. These discussions will highlight the promising developments in Radiopharm's pipeline, which aims to address significant medical needs.
Read more →-RADX
Aug 1, 2025▲ +13.8%on this news
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Date of this announcement Friday
Radiopharm Theranostics Limited has announced the issuance of 5 million unquoted securities as part of an employee incentive scheme. This notification was made on August 1, 2025, indicating the company's focus on promoting employee engagement. The unquoted securities will not be listed on the ASX, which allows for a more controlled and strategic distribution among employees. This issuance aligns with broader trends in management practices within the biopharma sector.
Read more →-RADX
Jul 29, 2025Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)
Radiopharm Theranostics has announced that it has received Investigational New Drug (IND) approval from the US FDA. This approval enables the company to initiate a Phase I therapeutic clinical study targeting B7H3 with its drug Betabart (RV-01). This marks a significant step forward in their clinical development efforts.
Read more →-RADX
Jul 29, 2025ASX ANNOUNCEMENT 29 July 2025 Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from D
Radiopharm Theranostics reported its financial results for fiscal year 2025, announcing significant progress in its clinical pipeline. The company is on track to complete enrollment of key cohorts for its investigational product RAD204 and has received a positive recommendation from its DSMC for dose escalation. Additionally, RAD101 has been granted Fast Track Designation by the FDA, indicating potential advantages in its development path. The company confirmed its cash runway, supporting continued operational activities as it approaches critical clinical milestones.
Read more →-RADX
Jul 28, 2025ASX ANNOUNCEMENT Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01) Lu177-B7H3 monoclonal antibody is first in class targeted rad
Radiopharm Theranostics has received FDA clearance for its Investigational New Drug application for Betabart (RV-01), a monoclonal antibody targeting B7H3. This development allows the company to initiate a first-in-human Phase I clinical trial, anticipated to start in the second half of 2025. RV-01 is designed to specifically target solid tumors with a strong affinity for the 4Ig isoform of B7H3, which is overexpressed in various aggressive tumor types. The antibody's characteristics may reduce the risk of adverse effects typically associated with similar therapies, making it a potentially innovative option in cancer treatment.
Read more →-RADX
Jul 22, 2025▲ +5.1%on this newsshared move
Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Dr. Oliver Sartor has been appointed to the Scientific Advisory Board of Radiopharm. His extensive experience in oncology and theranostics is expected to contribute positively to the company's strategic initiatives. This appointment aligns with Radiopharm's focus on advancing its clinical programs and enhancing its research capabilities.
Read more →-RADX
Jul 22, 2025ASX ANNOUNCEMENT 22 JULY 2025 DR OLIVER SARTOR APPOINTED TO RADIOPHARM SCIENTIFIC ADVISORY BOARD Sydney, Australia - 22 July 2025 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage bioph
Radiopharm Theranostics has appointed Dr. Oliver Sartor to its Scientific Advisory Board. Dr. Sartor is an acclaimed oncologist specializing in prostate cancer and brings extensive experience with several FDA-approved therapies. His leadership is expected to provide valuable insights as Radiopharm progresses with its radiopharmaceutical developments. This strategic addition reflects Radiopharm's commitment to advancing its innovative oncology offerings.
Read more →-RADX
Jul 21, 2025Radiopharm Receives $4.5M R&D Tax Incentive
Radiopharm Theranostics has secured a $4.5 million research and development tax incentive, which will bolster its ongoing clinical studies. This funding is expected to enhance the company's innovative efforts in the biopharma sector. The tax incentive underscores the potential of Radiopharm's projects and their significance in advancing therapeutic options.
Read more →-RADX
Jul 16, 2025▲ +5.4%on this newsshared move
ASX ANNOUNCEMENT Radiopharm Receives $4.5M R&D Tax Incentive Sydney, Australia - 16 July 2025 - Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company
Radiopharm Theranostics announced it has received a $4.5 million R&D tax refund from the Australian government for the 2024 financial year. This funding will aid in the development of its portfolio of radiopharmaceutical products aimed at diagnosing and treating cancers. The company's clinical pipeline includes various trials for solid tumor cancers, including advanced stages in lung, breast, and brain cancers. This financial support is crucial for advancing their innovative therapies in a field with significant unmet medical needs.
Read more →-RADX
Jun 30, 2025Quarterly Activities & Cash Report
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01), targeting B7H3. The company has also received IND approval from the US FDA to start this therapeutic clinical study. Additionally, positive updates have been shared regarding four ongoing programs, indicating progress in their clinical development efforts.
Read more →-RADX
Jun 27, 2025Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for 161Tb-KLK3-mAb Phase I Clinical Trial in Australia
Radiopharm Theranostics has entered into a clinical supply agreement with Cyclotek for the 161Tb-KLK3-mAb Phase I clinical trial in Australia. This collaboration marks a significant step in advancing their therapeutic offerings. The trial aims to evaluate the efficacy and safety of the new treatment in patients.
Read more →-RADX
Jun 24, 2025▲ +5.7%on this newsshared move
ASX ANNOUNCEMENT Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for 161 Tb-KLK3-mAb Phase I Clinical Trial in Australia RAD 402 preclinical data package complete; demonstrates safety and promising bi
Radiopharm Theranostics has entered into a clinical supply agreement with Cyclotek for the Phase 1 clinical trial of RAD 402, an innovative radiotherapeutic targeting prostate cancer. The agreement marks a significant step towards initiating the trial, with ethics approval expected soon. The preclinical data for RAD 402 indicates a favorable safety profile and biodistribution. The trial, expected to start in the second half of 2025, aims to explore the efficacy of Terbium-161 labeled monoclonal antibodies for treating prostate cancer, representing a novel approach in the field.
Read more →-RADX
Jun 12, 2025Notice Under Section 708A
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) after receiving IND approval from the US FDA. This marks a significant step in their therapeutic development targeting B7H3. The company has also shared positive updates across four of its clinical programs, indicating progress in its research efforts.
Read more →-RADX
Jun 12, 2025Application for quotation of securities – RAD
Radiopharm Theranostics has announced the initiation of a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01), following IND approval from the US FDA. The company has also provided positive updates across four clinical programs. This development marks a significant step forward for Radiopharm in its clinical endeavors.
Read more →-RADX
Jun 11, 2025RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
RAD has been granted Fast Track designation by the US FDA for its product RAD101, which is aimed at imaging metastases. This designation is intended to facilitate the development and review process, potentially accelerating the availability of RAD101 to patients. The designation highlights the product's promise in addressing unmet medical needs in cancer imaging.
Read more →-RADX
Jun 11, 2025▼ -5.8%on this newsshared move
Appendix 2A - Application for quotation of securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type New announcement Date of this announcement Wednesday
RADIOPHARM THERANOSTICS LIMITED announced the application for the quotation of 30,969,360 ordinary fully paid securities on June 11, 2025. This move follows previously communicated transactions, as outlined in an Appendix 3B submission. The announcement is part of the company's strategy to enhance its market presence and issued capital structure. The firm continues to engage with the Australian Securities Exchange (ASX) in line with its regulatory obligations.
Read more →-RADX
Jun 11, 2025▼ -5.8%on this newsshared move
ASX ANNOUNCEMENT 11 JUNE 2025 Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases RAD101 in U.S. Phase 2 clinical trial to distinguish between r
Radiopharm Theranostics has received Fast Track Designation from the U.S. FDA for its imaging product RAD101, aimed at distinguishing between recurrent disease and treatment effects of brain metastases. This development emphasizes the significant unmet medical need in diagnosing brain metastases, a condition affecting over 300,000 patients annually in the U.S. The company is currently involved in a Phase 2 clinical trial evaluating RAD101's diagnostic performance, with results expected later in 2025. This designation could expedite RAD101's development and review process due to its potential to address serious medical needs.
Read more →-RADX
Jun 10, 2025Proposed issue of securities – RAD
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. This marks a significant advancement in their clinical programs.
Read more →-RADX
Jun 4, 2025RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
RAD has successfully dosed the first patient in its therapeutic trial of 177Lu-RAD202. This marks a significant milestone in the development of this treatment, indicating progress in clinical research. The trial aims to evaluate the efficacy and safety of the drug, potentially offering new therapeutic options for patients.
Read more →-RADX
Jun 4, 2025ASX ANNOUNCEMENT 4 JUNE 2025 Radiopharm Theranostics Doses First Patient in Phase 1 HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors Phase 1 1 First-In-Human study designed to assess safet
Radiopharm Theranostics has announced the dosing of its first patient in the Phase 1 HEAT trial for 177Lu-RAD202, which targets advanced HER2-positive solid tumors. This trial will evaluate the safety and efficacy of RAD202 and marks an important milestone in the company's clinical development. The trial aims to provide a new therapeutic option for patients with metastatic HER2-positive cancers, addressing a significant unmet medical need. Previous studies demonstrated positive safety and efficacy data, reinforcing the potential benefits of this novel treatment.
Read more →-RADX
Jun 2, 2025RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
Radiopharm Theranostics has announced positive preclinical data for its Lu177-B7H3-mAb, indicating promising results that could enhance targeted therapies. This development may pave the way for further clinical studies and potential advancements in cancer treatment. The company is actively pursuing its research and development goals in this area.
Read more →-RADX
Jun 2, 2025▲ +11.2%on this newsshared move
ASX ANNOUNCEMENT Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake Supports plans to advance the RV01 program to first-in-human therapeutic ba
Radiopharm Theranostics has reported positive preclinical data for its radiopharmaceutical therapy, RV01, which targets solid tumours expressing the B7-H3 protein. The data showed favourable biodistribution and high tumour uptake, supporting the company's plan to advance the RV01 program to a first-in-human therapeutic study. The modification of the monoclonal antibody ensures a shorter half-life, potentially minimizing toxicities compared to traditional therapies. The company aims to submit an Investigational New Drug application in mid-2025, with a Phase 1 study slated to start in late 2025.
Read more →-RADX
May 30, 2025Change of Director’s Interest Notice (IT)
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) after receiving IND approval from the US FDA. The company has also shared positive updates regarding its clinical programs. This marks a significant advancement in their therapeutic development efforts.
Read more →-RADX
May 19, 2025ITM and RAD Sign Supply Agreement for n.c.a. Lutetium-177
ITM and RAD have entered into a supply agreement for n.c.a. Lutetium-177, which is expected to improve the accessibility of this important radiopharmaceutical. This partnership signifies a step forward in the development and distribution of Lutetium-177 for therapeutic applications. The agreement may bolster both companies' positions in the radiopharmaceutical market.
Read more →-RADX
May 19, 2025ASX ANNOUNCEMENT 19 MAY 2025 ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 Garching / Munich, Germany and Sydney, Australia, May 19 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharm
Radiopharm Theranostics has signed a supply agreement with ITM Isotope Technologies Munich SE for non-carrier-added Lutetium-177, which will be utilized in Radiopharm's clinical development pipeline, including key programs targeting various cancers. The supply agreement aims to ensure quality and reliability for the company's advanced assets, with intentions to enhance therapeutic options using ITM's radioisotope. This collaboration signals a step forward in the company's mission to provide effective treatments for cancers through targeted therapies.
Read more →-RADX
May 13, 2025Zachs Small-Cap Research RAD Initiating Coverage – Adding a Radio- isotope to Precision Oncology
Radiopharm Theranostics is making strides in precision oncology with its BetaBart (RV-01) program. The company has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. Additionally, they have dosed the first patient in a Phase 1/2a clinical study, showcasing progress in their clinical pipeline.
Read more →-RADX
May 12, 2025Acceleration of RAD204 Phase 1 dose escalation trial
Radiopharm Theranostics has accelerated the Phase 1 dose escalation trial of RAD204, marking a significant step in its clinical development. The company has successfully dosed the first patient, which reflects its ongoing commitment to advancing innovative therapies. This progress is expected to enhance the company's position in the biopharma landscape.
Read more →-RADX
May 12, 2025ASX ANNOUNCEMENT 12 May 2025 Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC) DSMC concluded that P
Radiopharm Theranostics announced a key milestone in its 177Lu-RAD204 Phase 1 clinical trial after receiving a positive recommendation from the Data Safety and Monitoring Committee (DSMC). The DSMC approved the continuation of the study without modifications, allowing the company to progress to a higher dose cohort. The company expects to complete enrollment for the next cohort by mid-2025, expanding the trial to include various advanced cancer types. The trial aims to explore the therapeutic potential of RAD204 in improving clinical outcomes for patients with PD-L1 positive cancers.
Read more →-RADX
Apr 29, 2025Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics has announced significant progress, including receiving IND approval from the US FDA for its Phase I study targeting B7H3 with BetaBart (RV-01). The company has also dosed its first patient in the Phase 1/2a clinical study of BetaBart. Additionally, positive updates have been shared across four of its clinical programs.
Read more →-RADX
Apr 29, 2025ASX ANNOUNCEMENT 29 April 2025 QUARTERLY ACTIVITIES AND CASH FLOW REPORT QUARTER ENDED 31 MARCH 2025 Sydney, Australia - 29 April 2025 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a
Radiopharm Theranostics announced its quarterly activities and cash flow report for the period ending March 31, 2025. The company secured US$5 million through a private placement with Lantheus, increasing Lantheus's stake to 12.16%. This funding will enhance Radiopharm's clinical pipeline, which includes multiple trials for solid tumors. Significant new clinical data was reported for RAD 101 and RAD202, showcasing their potential in cancer diagnostics and treatment.
Read more →-RADX
Apr 28, 2025First patient dosed in Phase IIb imaging for Brain Mets
Radiopharm Theranostics has successfully dosed its first patient in a Phase IIb imaging study targeting brain metastases. This milestone indicates progress in their clinical development efforts. The company aims to enhance imaging techniques for better diagnosis and treatment of brain metastases.
Read more →-RADX
Apr 28, 2025ASX ANNOUNCEMENT 28 APRIL 2025 Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected r
Radiopharm Theranostics has initiated its Phase 2b imaging study of 18F-RAD101 by dosing the first patient in the U.S. The study aims to evaluate the diagnostic performance of the radiopharmaceutical for identifying recurrent brain metastases from solid tumors. Results from an earlier Phase 2a trial indicated significant tumor uptake, suggesting that 18F-RAD101 could enhance diagnostic accuracy. The trial will involve 30 individuals and is significant in addressing an unmet medical need in brain cancer diagnosis.
Read more →-RADX
Mar 17, 2025▲ +6.9%on this news
New RAD202 data confirms positive tumor uptake
Radiopharm Theranostics has announced new data confirming positive tumor uptake for RAD202. This development is expected to enhance the therapeutic potential of the compound in clinical settings. The results indicate a favorable response in patients, which could lead to further advancements in cancer treatment strategies.
Read more →-RADX
Mar 17, 2025▲ +6.9%on this newsshared move
ASX ANNOUNCEMENT 17 MARCH 2025 New RAD202 data confirms positive tumor uptake and favorable biodistribution Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific
Radiopharm Theranostics announced promising new data for its oncology radiopharmaceuticals, particularly 68Ga-RAD202 and 177Lu-RAD202, at the European Molecular Imaging Meeting. The findings indicate effective targeting of HER2 in tumors, showing a favorable tumor-to-background ratio. Additionally, the therapy using 177Lu-RAD202 was noted to be well-tolerated, enhancing patient survival compared to traditional methods. The company is moving forward with First-In-Human studies to further explore these treatments, aiming to address unmet medical needs in HER2-positive metastatic cancer patients.
Read more →-RADX
Mar 15, 2025▲ +6.9%on this newsshared move
Notice of Extraordinary General Meeting/Proxy Form
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, positive updates have been shared regarding four of its clinical programs.
Read more →-RADX
Mar 13, 2025Participation in Leerink, NWR healthcare conferences
Radiopharm Theranostics is participating in the Leerink and NWR healthcare conferences. The company has recently received IND approval from the FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, the company has provided positive updates on its clinical programs, enhancing its profile in the biopharma sector.
Read more →-RADX
Mar 13, 2025ASX ANNOUNCEMENT 13 MARCH 2025 RADIOPHARM PARTICIPATION IN LEERINK, NWR HEALTHCARE CONFERENCES Sydney, Australia - 13 March 2025 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a world
Radiopharm Theranostics (ASX:RAD) has announced participation in the Leerink Partners Global Healthcare Conference and the NWR Virtual Healthcare Conference. Chief Medical Officer Dr. Dimitris Voliotis is set to engage in meetings with investors and present at the NWR conference on March 19, 2025. The company's commitment to developing radiopharmaceutical products positions it well in sectors of high unmet medical need.
Read more →-RADX
Mar 7, 2025Update – Notification regarding unquoted securities – RAD
Radiopharm Theranostics has made significant progress by dosing the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared regarding four ongoing programs.
Read more →-RADX
Mar 7, 2025Notification regarding unquoted securities – RAD
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates have been shared regarding four of its programs.
Read more →-RADX
Mar 7, 2025Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Update Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type Update to previous announcement Date of this announ
Radiopharm Theranostics Limited issued an update announcing the issuance of various unquoted equity securities under an employee incentive scheme. The announcement includes details on types, numbers, and existing classes of the securities, noting some are intended to remain unquoted on the ASX. The update serves to clarify information related to a previous announcement regarding these securities.
Read more →-RADX
Feb 28, 2025▼ -9.4%on this news· ran to +38% by day 3
Half Year Report and Appendix 4D 31 December 2024
Radiopharm Theranostics has made significant progress with the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and received IND approval from the US FDA for a therapeutic study targeting B7H3. The company has also reported positive updates across four of its clinical programs, indicating a strong pipeline and potential for future growth.
Read more →-RADX
Feb 28, 2025Radiopharm Theranostics Limited Appendix 4D Half-year report 1. Company details Name of entity: Radiopharm Theranostics Limited ABN: 57 647 877 889 Reporting period: For the half-year ended 31 December 2024 Previous peri
Radiopharm Theranostics Limited reported a reduced half-year loss of $18.73 million for the period ending December 31, 2024, down 20.90% from the previous year. Key progress was made with the RAD204 clinical trial, which is now approved to expand into multiple cancer types beyond its initial indication. The company has also strengthened its cash reserves to support ongoing projects. Financial statements have been reviewed by independent auditors who issued an unmodified opinion, reflecting the company's stable financial position despite previous losses.
Read more →-RADX
Feb 25, 2025▲ +5.2%on this newsshared move
Notification of cessation of securities – RAD
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also announced that it received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments mark significant progress for the company's clinical pipeline.
Read more →-RADX
Feb 24, 2025RAD to present at TD Cowen Annual Healthcare Conference
Radiopharm Theranostics (RADX) is set to present at the TD Cowen Annual Healthcare Conference. This event highlights the company's ongoing commitment to engage with the investment community and share updates on its clinical programs. The presentation is expected to provide insights into RAD's advancements and future plans.
Read more →-RADX
Feb 24, 2025ASX ANNOUNCEMENT 24 FEBRUARY 2025 RADIOPHARM TO PRESENT AT TD COWEN ANNUAL HEALTHCARE CONFERENCE Sydney, Australia - 24 February 2025 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a w
Radiopharm Theranostics (ASX:RAD) announced its participation in the TD Cowen's 45th Annual Healthcare Conference, taking place from March 3-5, 2025, in Boston, MA. CEO Riccardo Canevari is set to present on March 4, highlighting the company's investment proposition. Radiopharm focuses on developing advanced radiopharmaceutical products for diagnostic and therapeutic applications, particularly in oncology. The company aims to cater to high unmet medical needs with its distinct pipeline of cancer-targeting molecules.
Read more →-RADX
Feb 18, 2025Participation in B Riley Securities Radiopharma Conference
Radiopharm Theranostics is participating in the B Riley Securities Radiopharma Conference. The company has recently received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, they have reported positive clinical updates across four programs, showcasing their ongoing commitment to advancing radiopharmaceuticals.
Read more →-RADX
Feb 18, 2025▼ -5.7%on this newsshared move
ASX ANNOUNCEMENT 18 FEBRUARY 2025 RAD to participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference Sydney, Australia - 18 February 2025 - Radiopharm Theranostics (ASX:RAD, NASDAQ: RADX "Radi
Radiopharm Theranostics (ASX:RAD, NASDAQ: RADX) will participate in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference taking place on 28 February 2025 in New York. The conference will feature multiple small-to-mid cap companies in the biopharma and med-tech sectors, providing the company an opportunity to present its innovative oncology radiopharmaceuticals. Radiopharm has a strong focus on addressing high unmet medical needs with its deep pipeline of differentiated compounds, which includes a variety of cancer treatments currently in various stages of clinical trials.
Read more →-RADX
Feb 10, 2025Clinical trial data shows RAD 101 detects Brain Metastases
Recent clinical trial data reveals that RAD 101 effectively detects brain metastases. This promising development could enhance diagnostic capabilities in oncology, potentially leading to better patient management. The findings underscore the importance of RAD 101 in the evolving landscape of cancer treatment.
Read more →-RADX
Feb 10, 2025New clinical trial data highlights RAD 101 (18F-Pivalate) successfully detects Brain Metastases Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mp
Radiopharm Theranostics has announced the successful detection of brain metastases using RAD 101 (18F-Pivalate) through a novel imaging approach combining PET and mpMRI. A recent study published in the European Journal of Nuclear Medicine reported that all brain metastases from various primary solid tumors were detected with a high tumor-to-background ratio. The Phase 2b clinical trial for RAD 101 is currently recruiting participants in the U.S. to further evaluate its diagnostic performance in patients with suspected recurrent brain metastases.
Read more →-RADX
Jan 30, 2025January 2025 Newsletter
Radiopharm Theranostics has made significant strides in its clinical research, including the initiation of a Phase 1/2a study for BetaBart (RV-01) and receiving IND approval from the US FDA. The company has also reported positive updates across four of its programs, indicating progress in its therapeutic developments. Additionally, Dr. Oliver Sartor has been appointed to the Scientific Advisory Board.
Read more →-RADX
Jan 30, 2025ASX ANNOUNCEMENT 30 January 2025 QUARTERLY ACTIVITIES AND CASH FLOW REPORT QUARTER ENDED 31 DECEMBER 2024 Sydney, Australia - 30 January 2025 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a develope
Radiopharm Theranostics (ASX:RAD) reported significant developments in its quarterly activities and cash flow for the period ending December 31, 2024. The company received ethics approvals for multiple Phase 1 trials, including RAD202 for HER2-positive tumors and RAD204 expanding to target additional PD-L1-positive solid tumors. Moreover, promising preclinical results were disclosed for RAD 402, a KLK3-targeting radiotherapeutic. Additionally, strategic partnerships were highlighted, notably with AtomVie for developing 177Lu-BetaBart and Lantheus for advancing radiopharmaceuticals in Australia.
Read more →-RADX
Jan 24, 2025Cancer Research Milestones and 2025 Roadmap
Radiopharm Theranostics (ASX:RAD) has made notable advancements in cancer research during 2024. The company's CEO, Mr. Riccardo Canevari, highlighted key milestones, including progress in clinical trials and the establishment of strategic partnerships. Looking ahead, the company has outlined its priorities and roadmap for 2025.
Read more →-RADX
Jan 23, 2025Change in substantial holding
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its therapeutic candidate, Betabart (RV-01). The company has also received IND approval from the US FDA, marking a significant step in its clinical development. Additionally, Radiopharm has shared positive updates across four of its programs, indicating progress in its research efforts.
Read more →-RADX
Jan 21, 2025Appendix 2A - Application for quotation of securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type New announcement Date of this announcement Tuesday
RADIOPHARM THERANOSTICS LIMITED announced the application for the quotation of new securities on the ASX. The company plans to issue 133,333,333 ordinary fully paid shares at AUD 0.060 each to raise additional working capital. The securities will rank equally with existing securities in the same class. The announcement details the issuance process and compliance with ASX Listing Rules.
Read more →-RADX
Jan 10, 2025RAD American Depositary Receipt (ADR) FAQs
Radiopharm Theranostics has made significant progress by dosing the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to begin a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared across four of its programs, indicating a strong pipeline.
Read more →-RADX
Jan 10, 2025▲ +28.9%on this news· ran to +50% by day 1shared move
Lantheus increases shareholding in RAD with A$8m placement
Lantheus has announced an A$8 million placement to increase its shareholding in RAD. This strategic move reflects Lantheus's confidence in RAD's future prospects. The additional capital is expected to support RAD's ongoing projects and initiatives.
Read more →-RADX
Jan 10, 2025▲ +28.9%on this news· ran to +50% by day 1shared move
Response to ASX Cleansing Notice Validity Letter
Radiopharm Theranostics has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with BetaBart (RV-01). The company has also dosed the first patient in its Phase 1/2a clinical study of BetaBart. Additionally, positive updates have been shared across four of its clinical programs.
Read more →-RADX
Jan 10, 2025▲ +32.8%on this news· ran to +55% by day 1shared move
ASX ANNOUNCEMENT 09 JANUARY 2025 Lantheus increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) placement Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 million Placement at A$0.
Radiopharm Theranostics has announced the successful completion of a private placement with Lantheus Holdings Inc., raising US$5 million by issuing 133 million shares at a price of A$0.060 per share. This move increases Lantheus's shareholding in Radiopharm to 12.16%, making it the largest shareholder. Both companies have expressed satisfaction with their ongoing collaboration, particularly in the clinical development of radiopharmaceuticals. The capital raised will support Radiopharm's mission to develop innovative oncology agents.
Read more →-RADX
Dec 30, 2024Strategic Co-Development Partnership with Lantheus for Aus
Radiopharm Theranostics has announced a strategic co-development partnership with Lantheus for the Australian market. This collaboration aims to enhance the development of their therapeutic programs, particularly focusing on the BetaBart (RV-01) clinical study. The company has received IND approval from the US FDA to initiate Phase I studies targeting B7H3, marking a significant advancement in their research efforts.
Read more →-RADX
Dec 30, 2024ASX ANNOUNCEMENT 30 DECEMBER 2024 Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Ini
Radiopharm Theranostics has announced a strategic co-development partnership with Lantheus aimed at advancing the clinical development of innovative radiopharmaceuticals in Australia. Radiopharm will lead the clinical efforts, supported by Lantheus, which will cover all associated costs. The collaboration is set to include a clinical trial targeting multiple solid tumors. The agreement also includes potential milestone payments of up to USD 2 million for Radiopharm, contingent on specific development objectives being achieved.
Read more →-RADX
Dec 20, 2024RAD 202 receives approval to start Phase 1 therapeutic trial
Radiopharm Theranostics has received approval to initiate a Phase 1 therapeutic trial for RAD 202, targeting the B7H3 protein. This approval is a crucial milestone in the drug's development process, indicating progress in clinical research. The trial aims to evaluate the safety and efficacy of RAD 202 in patients.
Read more →-RADX
Dec 20, 2024ASX ANNOUNCEMENT 20 DECEMBER 2024 RAD 202 receives approval to start Phase 1 therapeutic trial Ethics approval received in Australia for the initiation of RAD's Phase 1 therapeutic trial of 177 Lu-RAD202 in Breast and Ga
Radiopharm Theranostics announced that it has received ethics approval to initiate a Phase 1 therapeutic trial of RAD 202, aimed at treating HER2-expressing solid tumors. The trial, named HEAT, will evaluate the safety and preliminary clinical activity of the 177Lu-labelled compound. This approval reflects the company's commitment to addressing the needs of patients who cannot tolerate existing standard treatments. The study will recruit participants across Australia with support from GenesisCare CRO.
Read more →-RADX
Dec 19, 2024Response to ASX Aware Letter
Radiopharm Theranostics has announced the dosing of the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). Additionally, the company has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. The company has also shared positive clinical updates across four programs.
Read more →-RADX
Dec 19, 2024Appendix 2A - Application for quotation of securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type New announcement Date of this announcement Thursday
Radiopharm Theranostics Limited announced its application for the quotation of securities on the ASX, specifically for 20,594,438 ordinary fully paid shares. This announcement is part of its compliance with ASX Listing Rules, and the securities are already classified under an existing class. As the application suggests an ongoing process, further details on the circumstances surrounding this issuance may be provided in future communications.
Read more →-RADX
Dec 18, 2024Change of Director’s Interest Notices x7
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its BetaBart (RV-01) therapy. The company has also received IND approval from the US FDA, allowing them to move forward with their therapeutic clinical study targeting B7H3. Additionally, positive updates have been shared regarding four of their clinical programs.
Read more →-RADX
Dec 10, 2024▼ -28.3%on this news· ran to -39% by day 3
Change of Director’s Interest Notice PH
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its therapeutic candidate, BetaBart (RV-01). The company has also received IND approval from the US FDA, allowing them to proceed with their clinical research. Additionally, they have shared positive updates regarding multiple clinical programs.
Read more →-RADX
Dec 10, 2024▼ -28.3%on this news· ran to -39% by day 3shared move
Completion of preclinical data package for RAD 402
Radiopharm Theranostics has completed the preclinical data package for RAD 402, marking a crucial step in its development. This achievement aligns with the company's ongoing efforts to advance its clinical programs, including recent positive updates across four initiatives. The completion of this data package is expected to facilitate further clinical trials.
Read more →-RADX
Dec 10, 2024▼ -28.3%on this news· ran to -39% by day 3shared move
ASX ANNOUNCEMENT 10 DECEMBER 2024 Completion of Preclinical Data Package for KLK3-Targeting Radiotherapeutic (RAD 402) Successful completion of preclinical studies with 161 Tb-labelled RAD 402 demonstrating safety and a
Radiopharm Theranostics announced the successful completion of a preclinical data package for its KLK3-targeting radiotherapeutic, RAD 402. Positive toxicology findings reported no adverse effects, and biodistribution studies demonstrated effective tumor targeting. The company plans to begin First-In-Human clinical studies in H2 2025. GMP manufacturing of RAD 402 is expected to be completed by Q1 2025, reinforcing its potential as a novel treatment option for advanced prostate cancer.
Read more →-RADX
Dec 2, 2024Constitution
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of Betabart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic clinical study targeting B7H3. Additionally, positive clinical updates were shared across four of their programs, indicating progress in their research efforts.
Read more →-RADX
Nov 27, 2024Radiopharm Theranostics on Sharewise webinar
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, Radiopharm has shared positive updates regarding four of its clinical programs.
Read more →-RADX
Nov 27, 2024Radiopharm achieves Nasdaq listing of ADS
Radiopharm Theranostics has successfully achieved a listing on Nasdaq for its American Depositary Shares (ADS). This milestone reflects the company's growth and commitment to advancing its clinical programs, including the ongoing Phase 1/2a study of BetaBart (RV-01). The company has also received positive feedback on its clinical updates across several programs.
Read more →-RADX
Nov 25, 2024Results of Meeting
Radiopharm Theranostics has announced the dosing of the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic clinical study targeting B7H3. Additionally, positive updates across four programs were shared, indicating progress in their clinical efforts.
Read more →-RADX
Nov 25, 2024Presentation to Annual General Meeting
Radiopharm Theranostics is set to present at its Annual General Meeting on November 25, 2024. The company has recently made significant progress, including the dosing of the first patient in its Phase 1/2a clinical study of BetaBart (RV-01) and receiving IND approval from the US FDA. These developments reflect the company's commitment to advancing its clinical programs.
Read more →-RADX
Nov 19, 2024Approval received to expand RAD204 Phase 1 trial
Radiopharm Theranostics has received approval to expand its Phase 1 trial for RAD204. This development marks a significant step in the company's clinical research efforts. The trial expansion is expected to enhance the understanding of RAD204's therapeutic potential. Additionally, the company has reported positive updates across several of its programs.
Read more →-RADX
Nov 18, 2024RAD 301 shows strong imaging potential in pancreatic cancer
Radiopharm Theranostics has reported promising results for RAD 301, showcasing its strong imaging capabilities in pancreatic cancer. The company has received positive clinical updates across its programs, including the recent IND approval from the US FDA for a new therapeutic study targeting B7H3. This positions RAD 301 as a significant player in the oncology imaging space.
Read more →-RADX
Oct 23, 2024RAD 202 data presented at 2024 EANM Annual Meeting
Radiopharm Theranostics presented data on RAD 202 at the 2024 EANM Annual Meeting, showcasing advancements in their research. The company has been actively involved in clinical studies and has received positive feedback regarding its programs. This presentation marks a significant step in their ongoing efforts to develop innovative therapies.
Read more →-RADX
Oct 23, 2024Change of Director’s Interest Notice – IT
Radiopharm Theranostics has announced significant progress in its clinical studies, including the dosing of the first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments highlight the company's commitment to advancing its therapeutic programs.
Read more →-RADX
Oct 21, 2024BAMF Health to manufacture & dose for RAD101 Phase 2b trial
BAMF Health has been selected to manufacture and dose for the RAD101 Phase 2b trial. This collaboration marks a significant step forward in the development of RAD101, showcasing the company's commitment to advancing its clinical programs. The trial aims to assess the efficacy and safety of RAD101 in patients.
Read more →-RADX
Oct 16, 2024RAD partners with AtomVie to develop B7H3 trial doses
Radiopharm Theranostics has announced a partnership with AtomVie to develop doses for the B7H3 trial. This collaboration aims to enhance the therapeutic potential of their candidate, Betabart (RV-01). The partnership is expected to accelerate the clinical development process, following recent positive updates from Radiopharm's various programs.
Read more →-RADX
Oct 15, 2024Notice of Annual General Meeting
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and received IND approval from the US FDA. The company is making significant progress in its clinical programs, showcasing positive updates across four different initiatives. This marks a promising step in their therapeutic development efforts.
Read more →-RADX
Oct 3, 2024Significant progress with B7-H3 targeting radio-antibody
Radiopharm Theranostics has made significant progress in its clinical development, receiving IND approval from the US FDA to initiate a Phase 1 therapeutic study targeting B7-H3 with its product BetaBart (RV-01). The company has also dosed its first patient in a Phase 1/2a clinical study. These advancements suggest a promising trajectory for the company's therapeutic programs.
Read more →-RADX
Oct 3, 2024Initial Director’s Interest Notice – ND
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its product BetaBart (RV-01). The company has also received IND approval from the US FDA to begin this therapeutic study targeting B7H3. Recent updates indicate positive progress across four of its clinical programs.
Read more →-RADX
Oct 2, 2024Appointment of Noel Donnelly as Non-Executive Director
Radiopharm Theranostics has appointed Noel Donnelly as a Non-Executive Director. This strategic move is expected to bolster the company's leadership and governance. Donnelly's experience is anticipated to contribute positively to the company's future endeavors and decision-making processes.
Read more →-RADX
Oct 2, 2024RAD to present at JonesResearch Radiopharma Day
Radiopharm Theranostics (RADX) is set to present at the upcoming JonesResearch Radiopharma Day. This presentation follows several positive clinical updates and the initiation of a Phase 1/2a clinical study for their product BetaBart (RV-01). The company has also received IND approval from the FDA to target B7H3 with this therapeutic study.
Read more →-RADX
Sep 30, 2024Corporate Governance Statement and Appendix 4G
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study for BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates have been shared across four of its clinical programs.
Read more →-RADX
Sep 30, 2024Annual Report
Radiopharm Theranostics has made significant progress, including the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and receiving IND approval from the US FDA for a therapeutic clinical study targeting B7H3. The company also shared positive updates across four of its programs, indicating a strong pipeline and future potential.
Read more →-RADX
Sep 30, 2024Annual Report to shareholders
Radiopharm Theranostics has made significant advancements, including the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and receiving IND approval from the US FDA. The company has also reported positive clinical updates across four programs, indicating a strong pipeline and commitment to innovation. These developments are promising for shareholders and the company's future.
Read more →-RADX
Sep 30, 2024ESG Report
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared across four of its clinical programs, indicating progress in its research efforts.
Read more →-RADX
Sep 19, 2024RAD Launching American Depositary Receipt (ADR) Program
Radiopharm Theranostics has announced the launch of its American Depositary Receipt (ADR) program, which is expected to enhance its visibility in the U.S. market. This initiative comes alongside positive updates from its clinical programs, including the recent IND approval from the FDA for a Phase I therapeutic study targeting B7H3 with Betabart (RV-01).
Read more →-RADX
Sep 18, 2024Change of Director’s Interest Notice (x6)
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and received IND approval from the US FDA for a therapeutic study targeting B7H3. The company has also provided positive updates across four of its clinical programs, indicating progress in its research and development efforts.
Read more →-RADX
Sep 18, 2024Becoming a substantial holder (PH)
Radiopharm Theranostics has made significant progress by receiving IND approval from the US FDA for its Phase 1 therapeutic clinical study targeting B7H3 with BetaBart (RV-01). The company has also dosed its first patient in the Phase 1/2a clinical study. Furthermore, positive updates have been shared across four of its programs, indicating a strong pipeline.
Read more →-RADX
Sep 6, 2024Diamond Equity Research Update 5 September 2024
Radiopharm Theranostics has made significant progress in its clinical studies, including the initiation of a Phase 1/2a study for Betabart (RV-01). The company has also received IND approval from the US FDA, allowing them to advance their therapeutic study targeting B7H3. Additionally, positive updates were shared regarding four of their programs.
Read more →-RADX
Sep 4, 2024August 2024 Newsletter
Radiopharm Theranostics has announced the dosing of the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company also reported positive clinical updates across four programs and received IND approval from the US FDA for a therapeutic study targeting B7H3. These developments indicate progress in their clinical research efforts.
Read more →-RADX
Aug 30, 2024Appendix 4E and Preliminary Final Report
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01), targeting B7H3. The company has also received IND approval from the US FDA for this therapeutic study. Additionally, positive updates were shared regarding four of their clinical programs, indicating progress in their research efforts.
Read more →-RADX
Aug 28, 2024Placement Options Range of Units and Top 20 Holders
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared across four of its programs, indicating progress in its clinical endeavors.
Read more →-RADX
Aug 27, 2024Ceasing to be a substantial holder
Radiopharm Theranostics has made several announcements regarding its clinical studies and updates. Notably, the company has dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01) and received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. The company continues to provide updates across its programs.
Read more →-RADX
Aug 26, 2024RAD increases ownership in Radiopharm Ventures to 75%
RAD has announced an increase in its ownership stake in Radiopharm Ventures to 75%. This strategic move reflects RAD's commitment to strengthening its position within the radiopharmaceutical sector. The increased ownership may provide RAD with enhanced control and influence over Radiopharm's operations and future developments.
Read more →-RADX
Aug 26, 2024Becoming a substantial holder
Radiopharm Theranostics has made significant progress by dosing the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). Additionally, the company received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Positive updates have been shared regarding multiple programs, indicating a strong pipeline.
Read more →-RADX
Aug 20, 2024Dr Dimitris Voliotis appointed Chief Medical Officer
Dr. Dimitris Voliotis has been appointed as the Chief Medical Officer of Radiopharm Theranostics. His extensive experience in the biopharma sector is anticipated to significantly contribute to the company's clinical development efforts. This strategic appointment aligns with Radiopharm's ongoing initiatives in advancing their therapeutic programs.
Read more →-RADX
Aug 14, 2024A$70m capital raising & Lantheus investment approved at EGM
Radiopharm Theranostics has successfully approved a capital raising of A$70 million and secured an investment from Lantheus at their Extraordinary General Meeting (EGM). This funding is expected to bolster their clinical programs, particularly in the development of their therapeutic candidates. The company has also received positive updates across its various clinical initiatives.
Read more →-RADX
Aug 14, 2024Results of Extraordinary General Meeting
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) after receiving IND approval from the US FDA. The company also reported positive updates across four of its clinical programs, indicating progress in its therapeutic developments. This marks a significant step forward for the company as it expands its clinical research efforts.
Read more →-RADX
Aug 14, 2024Presentation to Extraordinary General Meeting
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and has received IND approval from the US FDA. The company has also shared positive clinical updates across four of its programs. This marks a significant step forward in their therapeutic development efforts.
Read more →-RADX
Aug 9, 2024Update – Proposed issue of securities – RAD
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study for BetaBart (RV-01). Additionally, the company received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3 with the same compound. The company has also shared positive updates across four of its programs.
Read more →-RADX
Aug 9, 2024Prospectus
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study for Betabart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, positive clinical updates have been shared across four of its programs.
Read more →-RADX
Aug 5, 2024Radiopharm receives US$2.0 M payment from Lantheus
Radiopharm Theranostics has announced a receipt of US$2.0 million from Lantheus. This payment is expected to enhance their ongoing clinical studies and development efforts. The collaboration reflects a strong partnership between the two companies, potentially leading to further advancements in their therapeutic programs.
Read more →-RADX
Jul 26, 2024First patient dosed in Phase 1 therapeutic lung cancer trial
Radiopharm Theranostics has announced the dosing of the first patient in its Phase 1 clinical trial for BetaBart (RV-01), a therapeutic targeting B7H3. This milestone follows the recent IND approval from the US FDA, marking a significant step in the development of this treatment for lung cancer.
Read more →-RADX
Jul 26, 2024Radiopharm targets Nasdaq Listing by end of 2024
Radiopharm Theranostics is aiming for a Nasdaq listing by the end of 2024. The company has made significant progress, including receiving IND approval from the US FDA for a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, Radiopharm has reported positive clinical updates across four of its programs, indicating a strong pipeline.
Read more →-RADX
Jul 23, 2024FDA IND approval for Phase 2b trial in brain metastases
Radiopharm Theranostics has received FDA IND approval to initiate a Phase 2b clinical trial targeting brain metastases. This approval marks a crucial step in advancing their therapeutic approach. The trial aims to evaluate the efficacy and safety of their treatment in patients with this challenging condition.
Read more →-RADX
Jul 17, 2024Correction to Notice of Extraordinary General Meeting
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its product BetaBart (RV-01). The company has also received IND approval from the US FDA to begin a therapeutic clinical study targeting B7H3. Additionally, positive updates have been shared regarding four of their programs.
Read more →-RADX
Jul 16, 2024RAD notifies end of share agreements with Lind Partners
Radiopharm Theranostics has announced the termination of its share agreements with Lind Partners. This decision comes amidst ongoing clinical developments, including the dosing of the first patient in a Phase 1/2a clinical study for BetaBart (RV-01). The end of these agreements may raise concerns regarding the company's financial strategies and investor relations.
Read more →-RADX
Jul 5, 2024Change in substantial holding PH
Radiopharm Theranostics has commenced its Phase 1/2a clinical study of BetaBart (RV-01) after receiving IND approval from the US FDA. The company has also provided positive updates across four of its programs, showcasing progress in its clinical endeavors. This marks a significant step forward for Radiopharm in its therapeutic development.
Read more →-RADX
Jul 3, 2024GN20 Disclosure
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01). The company has also received IND approval from the US FDA to target B7H3 with this therapeutic study. Additionally, positive updates were shared regarding four of their clinical programs.
Read more →-RADX
Jun 28, 2024Diamond Equity Research Update 26 Jun 2024 – Radiopharm Extends Runway to Key Inflection Points
Radiopharm Theranostics has announced significant progress, including the extension of its operational runway to key inflection points. The company has received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, positive updates were shared across four clinical programs.
Read more →-RADX
Jun 27, 2024Investor webinar 3pm AEST Tuesday 2 July
Radiopharm Theranostics is hosting an investor webinar on July 2, 2024, at 3 PM AEST. The company has recently made significant strides, including receiving IND approval from the US FDA for a Phase I therapeutic clinical study targeting B7H3 with BetaBart (RV-01). This proactive approach aims to keep investors informed about ongoing developments.
Read more →-RADX
Jun 27, 20241H24 B. Riley Radiopharma Industry Note Review 26 Jun 2024
Radiopharm Theranostics has made significant progress in its clinical studies, including the dosing of the first patient in its Phase 1/2a study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments indicate a positive trajectory for Radiopharm's research and clinical efforts.
Read more →-RADX
Jun 25, 2024Radiopharm Theranostics completes A$70 million placement
Radiopharm Theranostics has successfully completed a A$70 million placement to support its ongoing clinical programs. The company has received positive updates across four clinical programs, including the initiation of a Phase I therapeutic study targeting B7H3 with its product BetaBart (RV-01). This funding will help advance their research and development efforts.
Read more →-RADX
Jun 25, 2024Lantheus Strategic Investment and Capital Raise Presentation
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates have been provided across four of its clinical programs.
Read more →-RADX
Jun 25, 2024Reinstatement to Quotation
Radiopharm Theranostics has been reinstated to quotation following positive developments in its clinical programs. The company has received IND approval from the US FDA to initiate a Phase I therapeutic study targeting B7H3 with its product BetaBart (RV-01). Additionally, the company has successfully dosed its first patient in a Phase 1/2a clinical study.
Read more →-RADX
Jun 24, 2024Suspension from Quotation
Radiopharm Theranostics has been suspended from quotation, raising concerns about its financial health. The company has faced scrutiny due to a lack of recent positive developments and ongoing challenges. This suspension may impact investor confidence and the company's market position.
Read more →-RADX
Jun 20, 2024Radiopharm Receives Strategic Investment for up to A$18 mill
Radiopharm Theranostics has secured a strategic investment of up to A$18 million to bolster its clinical programs. This funding is expected to enhance the development of its therapeutic candidates, particularly in ongoing clinical studies. The company has also reported positive updates across its various programs, indicating strong progress in its research efforts.
Read more →-RADX
Jun 20, 2024Trading Halt
Radiopharm Theranostics has announced a trading halt, with ongoing updates regarding their clinical studies and capital raising efforts. The company has recently dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01) and received IND approval from the US FDA for another therapeutic study targeting B7H3. Further announcements are expected in the coming months.
Read more →-RADX
May 23, 2024Change in substantial holding NanoMab
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01). The company has also received IND approval from the US FDA to target B7H3 with this therapeutic study. Positive updates have been shared across multiple programs, indicating progress in their clinical endeavors.
Read more →-RADX
May 8, 2024RAD to be featured at B. Riley Securities Healthcare events
Radiopharm Theranostics (RADX) will be featured at upcoming B. Riley Securities Healthcare events. The company has recently received IND approval from the FDA to initiate a Phase I therapeutic clinical study targeting B7H3 with its product BetaBart (RV-01). Additionally, RAD has provided positive updates across four clinical programs, enhancing its profile in the market.
Read more →-RADX
Apr 22, 2024Radiopharm Ventures institutional & VC presentation
Radiopharm Ventures has announced significant progress in its clinical studies, including the initiation of a Phase 1/2a study for BetaBart (RV-01) and receiving IND approval from the US FDA. The company has also provided positive updates across four of its programs, indicating a strong pipeline for future developments.
Read more →-RADX
Mar 26, 2024Initial Director’s Interest Notice PH
Radiopharm Theranostics has made significant progress in its clinical research, having dosed the first patient in a Phase 1/2a study for BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate this therapeutic clinical study targeting B7H3. Additionally, positive updates have been shared across four of its programs, indicating a strong pipeline.
Read more →-RADX
Mar 26, 2024Final Director’s Interest Notice MB
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) after receiving IND approval from the US FDA. The company has also shared positive updates across four of its clinical programs. This marks a significant advancement in their therapeutic development efforts.
Read more →-RADX
Mar 26, 2024Board Changes
Radiopharm Theranostics has made significant strides in its clinical development, including the dosing of its first patient in a Phase 1/2a study for BetaBart (RV-01). Additionally, the company has received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments indicate progress in their research pipeline.
Read more →-RADX
Mar 19, 2024RAD to present at NWR Virtual Healthcare Conference
Radiopharm Theranostics (RADX) is set to present at the NWR Virtual Healthcare Conference. The company has recently made strides in its clinical programs, including dosing the first patient in a Phase 1/2a clinical study of BetaBart (RV-01). This participation highlights RAD's commitment to advancing its therapeutic developments.
Read more →-RADX
Mar 18, 2024Diamond Equity Research – Advancing Pipeline with Strategic Clinical Developments
Radiopharm Theranostics is advancing its clinical pipeline with the initiation of a Phase 1/2a study for BetaBart (RV-01). The company has also received IND approval from the US FDA to target B7H3 with this therapeutic. Additionally, positive updates have been reported across four of its programs, indicating progress in its clinical developments.
Read more →-RADX
Mar 15, 2024RAD 301 and 302 data shows value of targeting avb6-integrin
Radiopharm Theranostics has reported positive updates regarding its clinical programs, including the dosing of the first patient in the Phase 1/2a study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a Phase I therapeutic clinical study targeting B7H3. These developments highlight the potential value of targeting avb6-integrin in their research.
Read more →-RADX
Mar 14, 2024Initiation Research Report Radiopharm (ASX:RAD) Near to market imaging drug
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its imaging drug, BetaBart (RV-01). The company has also received IND approval from the US FDA to begin therapeutic studies targeting B7H3. Positive updates have been shared regarding multiple programs, indicating progress in their clinical pipeline.
Read more →-RADX
Mar 13, 2024March 2024 Newsletter
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study for BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared across four of its clinical programs.
Read more →-RADX
Mar 6, 2024Multiple RAD301 data releases to be presented at EMIM
Radiopharm Theranostics is set to present multiple data releases related to RAD301 at the upcoming EMIM event. This follows a series of positive clinical updates across their programs, showcasing the company's progress in the biopharma sector. The presentations are expected to provide insights into their ongoing clinical studies and future directions.
Read more →-RADX
Mar 4, 2024B Riley Securities Radiopharma Conference Presentation
Radiopharm Theranostics has made significant strides by initiating a Phase 1/2a clinical study of BetaBart (RV-01) and receiving IND approval from the US FDA. The company also provided positive updates across four of its clinical programs. These developments highlight the company's ongoing commitment to advancing its therapeutic offerings.
Read more →-RADX
Mar 1, 2024Half Yearly Report and Accounts
Radiopharm Theranostics has reported significant progress in its clinical studies, including the initiation of a Phase 1/2a clinical trial for BetaBart (RV-01). The company has also received IND approval from the US FDA for a therapeutic study targeting B7H3. Furthermore, positive updates have been shared across four of its programs, indicating a strong pipeline.
Read more →-RADX
Mar 1, 2024Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301
Radiopharm Theranostics has announced the initiation of dosing in a Phase 1 clinical study for RAD 301, aimed at improving pancreatic imaging. This study marks a significant step forward in the company's research efforts. The focus on pancreatic imaging is crucial, given the challenges in diagnosing pancreatic conditions effectively.
Read more →-RADX
Feb 28, 2024Pilot Study Validates RAD Terbium-161 Radiotherapeutics
The pilot study has successfully validated RAD Terbium-161 radiotherapeutics, indicating promising results for future clinical applications. This development enhances the credibility of the technology and may lead to further advancements in the field of radiopharmaceuticals. The positive outcomes from this study could significantly impact treatment options for patients.
Read more →-RADX
Feb 23, 2024Participation in B. Riley Securities Radiopharma Conference
Radiopharm Theranostics is set to participate in the B. Riley Securities Radiopharma Conference. The company has recently made strides in its clinical programs, including dosing the first patient in a Phase 1/2a clinical study of BetaBart (RV-01) and receiving IND approval from the FDA for a new therapeutic study targeting B7H3.
Read more →-RADX
Feb 21, 2024Radiopharm receives $1.9 M advance on FY24 R&D tax incentive
Radiopharm Theranostics has secured a $1.9 million advance related to its R&D tax incentive for the fiscal year 2024. This funding is expected to bolster the company's research efforts and support ongoing projects. The advance reflects confidence in Radiopharm's innovative capabilities and future potential.
Read more →-RADX
Feb 6, 2024RAD Share Facility Agreement of up to A$12.5m addendum
Radiopharm Theranostics has announced an addendum to its share facility agreement, increasing the funding capacity to A$12.5 million. This financial boost is expected to support the company's clinical studies and development efforts. Positive clinical updates across multiple programs further enhance the company's outlook.
Read more →-RADX
Feb 6, 2024RAD secures Share Facility Agreement of up to A$12.5m
Radiopharm Theranostics (RADX) has successfully secured a Share Facility Agreement worth up to A$12.5 million. This funding is expected to bolster the company's financial position and support its ongoing clinical programs. The announcement reflects RAD's proactive approach to capital raising in the biopharma sector.
Read more →-RADX
Feb 5, 2024RAD 502 can halt tumour progression and prolong survival
RAD 502 has demonstrated the ability to halt tumor progression and extend patient survival, according to recent clinical updates. The treatment is currently being evaluated in ongoing studies, with positive outcomes reported. This advancement highlights the potential of RAD 502 in improving cancer treatment options.
Read more →-RADX
Jan 24, 2024Placement of Entitlement Offer Shortfall
Radiopharm Theranostics has announced the placement of entitlement offer shortfall. This comes alongside positive clinical updates and the initiation of a Phase 1/2a clinical study for BetaBart (RV-01). The company has also received IND approval from the US FDA to begin a therapeutic study targeting B7H3.
Read more →-RADX
Jan 24, 2024Investor Presentation
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study for BetaBart (RV-01). This follows the company's recent IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates were shared regarding four of their clinical programs.
Read more →-RADX
Jan 5, 2024Jones Research Update 4 Jan 2024
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates have been reported across four of its programs, indicating progress in its clinical pipeline.
Read more →-RADX
Dec 27, 20232nd Australian site for Nanomab-PDL-1 Phase 1 trial
Radiopharm Theranostics has announced the initiation of a second Australian site for its Nanomab-PDL-1 Phase 1 trial. This expansion signifies a step forward in the clinical development of the therapy, aimed at enhancing treatment options. The trial's progression is a positive indicator of the company's commitment to advancing its research efforts.
Read more →-RADX
Dec 22, 2023Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan
Radiopharm Theranostics has announced the opening of a Phase 1 therapeutic trial for non-small cell lung cancer (NSCLC) starting January 4, 2024. This trial aims to evaluate the efficacy of their drug targeting B7H3. The initiation of this trial marks a notable advancement in the company's clinical research efforts.
Read more →-RADX
Dec 18, 2023RAD’s 68Ga-Trivehexin (RAD301) featured in prestigious peer-reviewed journal RSC Medicinal Chemistry
RAD's 68Ga-Trivehexin (RAD301) has been highlighted in the esteemed peer-reviewed journal RSC Medicinal Chemistry. This recognition is expected to bolster the visibility of RAD's research and may attract further interest from the scientific community. The publication underscores the significance of RAD301 in the field of medicinal chemistry.
Read more →-RADX
Dec 15, 2023Change of Director’s Interest Notice x5
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for its treatment BetaBart (RV-01). The company has also received IND approval from the US FDA to commence this study targeting B7H3. Additionally, positive updates have been shared regarding four of its clinical programs.
Read more →-RADX
Dec 14, 2023Diamond Equity Research Update 13 Dec 2023
Radiopharm Theranostics has made significant progress by dosing the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). Additionally, the company received Investigational New Drug (IND) approval from the US FDA to initiate this therapeutic study targeting B7H3. Recent updates indicate positive developments across four of their clinical programs.
Read more →-RADX
Dec 8, 2023Completion of Entitlement Offer
Radiopharm Theranostics has successfully completed its entitlement offer, reflecting strong investor confidence. The company has also provided positive updates on its clinical programs, including the initiation of a Phase 1/2a study for BetaBart (RV-01). Additionally, the recent IND approval from the FDA positions the company favorably for future developments.
Read more →-RADX
Dec 7, 2023Change of Director’s Interest Notice – PH IT RC
Radiopharm Theranostics has announced significant progress in its clinical studies, including the dosing of the first patient in a Phase 1/2a study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These developments indicate a positive trajectory for the company's research initiatives.
Read more →-RADX
Nov 22, 2023Amended Constitution
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. This marks a significant advancement in their clinical development pipeline.
Read more →-RADX
Nov 22, 2023Radiopharm receives $4.85M R&D tax incentive
Radiopharm Theranostics has secured a $4.85 million research and development tax incentive. This funding is expected to bolster their ongoing clinical studies and enhance their research capabilities. The incentive reflects the company's commitment to advancing their therapeutic programs, particularly in the field of radiopharmaceuticals.
Read more →-RADX
Nov 22, 2023Change of Director’s Interest Notice – RC
Radiopharm Theranostics has announced a change in director's interest, alongside various updates regarding their clinical studies and research initiatives. The company is actively involved in multiple programs, including the Phase 1/2a clinical study of BetaBart (RV-01). Recent announcements also highlight the appointment of Dr. Oliver Sartor to their Scientific Advisory Board.
Read more →-RADX
Nov 21, 2023Entitlement Offer closing date extended to 1 December 2023
Radiopharm Theranostics has announced an extension of the closing date for its entitlement offer to December 1, 2023. This decision aims to provide more investors the opportunity to participate in the funding initiative. The extension reflects the company's commitment to enhancing investor engagement and securing necessary capital for future projects.
Read more →-RADX
Nov 16, 2023Notification of Release of Shares from Escrow
Radiopharm Theranostics has announced the release of shares from escrow, which is a significant corporate update. This notification is part of ongoing announcements related to the company's clinical studies and capital raising efforts. The company has been active in clinical trials, including a recent Phase 1/2a study of BetaBart (RV-01).
Read more →-RADX
Nov 16, 2023Results of Annual General Meeting
Radiopharm Theranostics has announced significant developments, including the dosing of the first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. These updates highlight the company's ongoing commitment to advancing its clinical programs.
Read more →-RADX
Nov 15, 2023Bell Potter Healthcare Conference Presentation
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and has received IND approval from the US FDA. The company also shared positive clinical updates across four of its programs. This presentation at the Bell Potter Healthcare Conference highlights their advancements in therapeutic development.
Read more →-RADX
Nov 8, 2023Entitlement Offer Documents
Radiopharm Theranostics has announced the dosing of its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). Additionally, the company received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. The announcement highlights positive clinical updates across four programs, indicating progress in their research and development efforts.
Read more →-RADX
Oct 31, 2023Investor Presentation – Entitlement Offer
Radiopharm Theranostics has announced an investor presentation regarding its entitlement offer. The company is making strides in its clinical programs, including the initiation of a Phase 1/2a study for BetaBart (RV-01). Additionally, it has received IND approval from the US FDA to begin a therapeutic clinical study targeting B7H3.
Read more →-RADX
Oct 31, 2023Investor webinar
Radiopharm Theranostics has announced a series of updates, including the dosing of the first patient in its Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive clinical updates have been provided across four programs.
Read more →-RADX
Oct 31, 2023Entitlement Offer to raise approximately $10 million
Radiopharm Theranostics has announced an entitlement offer to raise around $10 million. This move comes alongside positive clinical updates and the recent approval from the US FDA for a Phase I study targeting B7H3 with Betabart (RV-01). The company is actively advancing its clinical programs, indicating a strong pipeline.
Read more →-RADX
Oct 20, 2023Diamond Equity Research Update Oct 2023 Valuation at 70 cents per share
Radiopharm Theranostics has been highlighted in a recent update by Diamond Equity Research, which values the company at 70 cents per share. The update includes positive news regarding the company's clinical trials and FDA approvals. Notably, the company has initiated a Phase I study targeting B7H3 with its product BetaBart (RV-01).
Read more →-RADX
Oct 20, 2023Diamond Equity Research Update Sep 2023 Valuation at 70 cents per share
Diamond Equity Research has updated its valuation for Radiopharm Theranostics (RADX) to 70 cents per share. This update comes amidst positive clinical developments, including the dosing of the first patient in a Phase 1/2a clinical study of BetaBart (RV-01) and recent FDA IND approval for a new therapeutic study targeting B7H3. The outlook appears optimistic based on these advancements.
Read more →-RADX
Oct 18, 2023Entitlement Offer cleansing notice under section 708AA
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and received IND approval from the US FDA for a therapeutic study targeting B7H3. The company has also provided positive updates across four of its clinical programs, indicating progress in its research and development efforts.
Read more →-RADX
Oct 18, 2023Notice of Annual General Meeting/Proxy Form
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and has received IND approval from the US FDA to start a therapeutic clinical study targeting B7H3. The company has also shared positive updates across four of its programs, indicating progress in its clinical endeavors.
Read more →-RADX
Oct 17, 2023FDA green light for diagnostic Phase 1 pancreatic trial
Radiopharm Theranostics has received FDA approval to initiate a Phase 1 clinical trial for a diagnostic targeting pancreatic conditions. This trial represents a significant step forward in the company's efforts to develop innovative diagnostic tools. The approval is expected to enhance the understanding and treatment of pancreatic diseases.
Read more →-RADX
Oct 9, 2023RAD receives approval for Phase 1 therapeutic study of NSCLC
Radiopharm Theranostics (RADX) has received FDA approval to initiate a Phase 1 therapeutic study targeting B7H3 in non-small cell lung cancer (NSCLC). This study represents an important advancement in RAD's clinical research efforts. The approval is expected to facilitate further investigations into the efficacy of their therapeutic approach.
Read more →-RADX
Sep 28, 2023Appendix 4G
Radiopharm Theranostics has successfully dosed its first patient in a Phase 1/2a clinical study of BetaBart (RV-01). The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Positive clinical updates were shared across four programs, indicating progress in their research efforts.
Read more →-RADX
Sep 28, 2023Corporate Governance Statement
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01), targeting B7H3. The company has also received IND approval from the US FDA to commence this therapeutic clinical study. Additionally, positive updates have been shared regarding four of their clinical programs, indicating progress in their research efforts.
Read more →-RADX
Aug 31, 2023Appendix 4E and FY23 Financial Report
Radiopharm Theranostics has made significant progress with its BetaBart (RV-01) program, having dosed the first patient in a Phase 1/2a clinical study. The company has also received IND approval from the US FDA to initiate a therapeutic clinical study targeting B7H3. Additionally, positive updates have been shared across four programs, indicating a strong pipeline.
Read more →-RADX
Aug 24, 2023TerThera Terbium-161 isotope supply agreement expanded
TerThera has expanded its supply agreement for the Terbium-161 isotope, indicating a strategic move to enhance its operational capacity. This expansion is expected to support ongoing clinical trials and future projects. The agreement reflects the company's commitment to advancing its therapeutic offerings in radiopharmaceuticals.
Read more →-RADX
Aug 18, 2023EGM Presentation
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) after receiving IND approval from the US FDA. The company has also shared positive clinical updates across four of its programs. This marks a significant advancement in their therapeutic development efforts.
Read more →-RADX
Aug 8, 2023Change of Director’s Interest Notice IT
Radiopharm Theranostics has announced the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and has received IND approval from the US FDA. The company has also shared positive clinical updates across four programs. This marks a significant step forward in their therapeutic development efforts.
Read more →-RADX
Jul 20, 2023Dr Sherin Al-Safadi appointed VP Medical & Corporate Affairs
Dr. Sherin Al-Safadi has been appointed as the Vice President of Medical and Corporate Affairs at Radiopharm Theranostics. Her extensive background in medical affairs is anticipated to strengthen the company's strategic initiatives. This leadership change is part of Radiopharm's ongoing efforts to enhance its position in the biopharma industry.
Read more →Competitive Position
How RADX ranks across every disease it competes inCompetitive Position is a premium feature
See how RADX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial